Objective: To investigate the impact of dopaminergic therapy on the onset of motor complications in Parkinson's disease (PD).

Methods: Two clinical questions were identified. (1) Whether levodopa (LD) dose, LD treatment duration, the time from disease onset to initiation of LD can predict the onset of motor complications in PD? and (2) whether dopamine agonists (DA) used in de novo patients can delay the onset of motor complications? Literatures on observation studies of factors associated with motor complications and randomized controlled trials (RCTs) of DA compared to LD in treatment of de novo patients published before May 2008 were retrieved from Pubmed, EMbase, and Cochrane Database. Methodology quality was critically assessed.

Results: 12 articles on the first question were selected, including one RCT, five cohort studies, six case-control studies. Six RCTs on the second question were selected. Because of clinical heterogeneity among the researches thus retrieved, meta-analysis was not conducted, and qualitative analysis showed that initial LD dose, LD dose per kilogram body weight, accumulated LD dose, and accumulated LD equivalent dose might be independent factors associated with motor complications. The time from disease onset to initiation of LD was not correlated with motor complications. DA as initial treatment was associated with later occurrence of dyskinesias (CALM-PD: HR = 0.37, 95% CI: 0.25 - 0.56, P < 0.001; PELMOPET: HR = 0.48, 95% CI = 0.29 - 0.80, P < 0.001; Ropinirole 056: HR = 0.4, 95% CI: 0.2 - 0.8, P = 0.007; REAL-PET: HR = 8.28, 95% CI: 2.46 - 27.93, P < 0.001). The relationship between LD treatment duration and motor complications could not be concluded from present evidence.

Conclusion: Initial LD dose, LD dose per kilogram body weight, accumulated LD dose, and accumulated LD equivalent dose may be independent factors associated with motor complications. The time from disease onset to initiation of LD was not correlated with motor complications.

Download full-text PDF

Source

Publication Analysis

Top Keywords

motor complications
36
onset motor
12
time disease
12
disease onset
12
onset initiation
12
factors associated
12
associated motor
12
motor
10
complications
9
dose
9

Similar Publications

The anti-dyskinetic effect of the clinic-ready mGluRpositive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat.

Naunyn Schmiedebergs Arch Pharmacol

January 2025

Neurodegenerative Disorders Research Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada.

L-3,4-dihydroxyphenylalanine (L-DOPA) remains the main treatment for motor symptoms of Parkinson's disease (PD). However, chronic use is associated with the development of complications such as L-DOPA-induced dyskinesia. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of L-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of L-DOPA.

View Article and Find Full Text PDF

HIV-associated neurocognitive disorder (HAND) is a complex neurological complication resulting from human immunodeficiency virus (HIV) infection, affecting about 50% of individuals with HIV and significantly diminishing their quality of life. HAND includes a variety of cognitive, motor, and behavioral disorders, severely impacting patients' quality of life and social functioning. Although combination antiretroviral therapy (cART) has greatly improved the prognosis for HIV patients, the incidence of HAND remains high, underscoring the urgent need to better understand its pathological mechanisms and develop early diagnostic methods.

View Article and Find Full Text PDF

Multiple sclerosis (MS) is the most common cause of disability in young adults due to several motor, sensory, and cognitive symptoms. However, little is still known about the impact of psychological, cognitive, and social-support variables on subjective disability. This study is aimed at exploring the role of clinical, psychological, cognitive, and social-support variables in predicting disability levels as perceived by persons with multiple sclerosis (pwMS).

View Article and Find Full Text PDF

From diagnosis to treatment: exploring the mechanisms underlying optic neuritis in multiple sclerosis.

J Transl Med

January 2025

Department of Anesthesiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, People's Republic of China.

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, commonly causing sensory disturbances, motor weakness, impaired gait, incoordination and optic neuritis (ON). According to the statistics, up to 50% of MS patients experience vision problems during the disease course, suffering from blurred vision, pain, color vision deficits, and even blindness. Treatments have progressed from corticosteroids to therapies targeted against B/T cells.

View Article and Find Full Text PDF

Identifying impairments and compensatory strategies for temporal gait asymmetry in post-stroke persons.

Sci Rep

January 2025

Neurorehabilitation Research Center, Kio University, 4-2-2 Umaminaka, Kitakatsuragi-gun, Koryo, Nara, 635-0832, Japan.

In post-stroke persons, temporal gait asymmetry (TGA) during comfortable gait involves a combination of pure impairments and compensatory strategies. In this study, we aimed to differentiate between pure impairments and compensatory strategies underlying TGA in post-stroke individuals and identify associated clinical factors. We examined 39 post-stroke individuals who participated in comfortable walking speed (CWS) and rhythmic auditory cueing (RAC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!